Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Trading Down 1.6 %

Shares of Minerva Neurosciences stock opened at $1.79 on Friday. Minerva Neurosciences has a 1-year low of $1.77 and a 1-year high of $7.53. The firm’s 50-day moving average price is $2.18 and its two-hundred day moving average price is $2.41. The stock has a market capitalization of $12.52 million, a price-to-earnings ratio of -4.07 and a beta of 0.12.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Northern Trust Corp increased its stake in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,878 shares of the biopharmaceutical company’s stock after purchasing an additional 13,829 shares during the quarter. Northern Trust Corp owned about 0.53% of Minerva Neurosciences worth $82,000 at the end of the most recent quarter. Institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.